Benjamin Caplan, MD’s Post

Up to 40% of people being treated for cancer use cannabis to help with side effects like pain and anxiety. But with evidence from studies on cannabis lacking, clinicians feel ill-equipped to answer patient questions about its safety and effectiveness. https://go.nih.gov/sG3IxXP

𝗪𝗶𝘁𝗵 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝗳𝗿𝗼𝗺 𝗡𝗙𝗟 𝗼𝘄𝗻𝗲𝗿 𝗝𝗲𝗳𝗳𝗿𝗲𝘆 𝗟𝘂𝗿𝗶𝗲, 𝗜𝗰𝗲𝗹𝗮𝗻𝗱𝗶𝗰 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗰𝗹𝗼𝘀𝗲𝘀 𝗦𝗲𝗿𝗶𝗲𝘀 𝗔 𝗳𝗼𝗿 𝗼𝗿𝗮𝗹 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿'𝘀 𝗱𝗿𝘂𝗴 A father-and-son biotech with ties to Iceland and Philadelphia has put together a €26.5 million Series A to develop oral treatments for Alzheimer’s disease and …Hakon Hakonarson , Arctic Therapeutics https://lnkd.in/d7F9uSTY

Over 90% of American #SickleCellDisease (SCD) patients are Black or African American, contributing to a history of #underfunding and stigma. Patients (even children) in severe pain are often misconstrued as drug-seekers. I spoke with John Paderi, who recognised from his training at the Stanford Byers Center for Biodesign that the future of sickle cell pain management should empower patients by moving care into the home setting. He's developing an accessible, self-administered drug at IHP Therapeutics. Tune in to hear about why #opioids are inadequate, how IHP developed their new molecule, and his experience as #ChiefScientificOfficer — risks, opportunities, and strategy. We also explore how he integrates Biodesign with his #academia training, surprising parallels between SCD and #migraines, and his most rewarding moment at IHP so far! https://lnkd.in/g_ZVfHsq

Chronic pain affects millions of Canadians, with current treatments often falling short or causing serious side effects. We’re excited to support Zymedyne Therapeutics and its breakthrough work in chronic pain treatment through our AICE-Validate program. Dr. Gerald Zamponi’s team has discovered that pain regulators found in cell channels can be inhibited, and affect their interaction with potent analgesic effects. The team has identified a novel class of drugs that targets this interaction to provide pain relief, paving the way for safer, non-addictive therapies that could transform how we manage pain. Learn more: https://bit.ly/4fqmF2R #ChronicPain #PainManagement #AICEValidate #AlbertaInnovates Bindi Ferguson | Jose Raez | Tim Murphy | Nate Glubish

For many cancer patients, the use of cannabis to combat some of the side effects of treatment, such as nausea or insomnia, is a welcome therapy. But, with the persistent stigmatization of this modality, many health care providers feel uncertain in this terrain. We share advice on how to provide guidance about medical cannabis in our latest episode of How Healing Works. Follow the link to learn how you can confidently support the #WholePersonHealth of patients with this complementary therapy. 🔗 https://apple.co/3KsXnDv

✨ Inhibikase Therapeutics, as featured by Professor Ari Zoldan - Public and Investor Relations Expert on Investing.com, is at the forefront of developing targeted therapies that may significantly improve the quality of life for individuals living with Parkinson’s disease. Their innovative approach targets c-Abl kinase, a key factor in the disease process. Recent clinical trials have shown promising results, with their lead candidate, risvodetinib, demonstrating a favorable safety profile and potential disease-modifying effects. As they progress to late-stage trials, the future of Parkinson’s treatment looks promising. Explore the full article to learn more about how these breakthroughs could shape the future of patient care [link in the comments] 🔗 #Healthcare #Innovation #Parkinsons #InhibikaseTherapeutics #AriZoldan

This report, based on a series of initial interviews, and augmented by an extensive survey to which 25 countries responded, describes policies and practices adopted by countries to address some challenges specific to oncology medicines. #admin To learn health economic evaluation and decision analytic models: https://lnkd.in/d9s6-iTk.

"I think the future [of Alzheimer's care is] going to lay—just like in cancer—with #CombinationTherapy and #PrecisionMedicine driven by #biomarkers." - Howard Fillit, MD This morning, ADDF Co-Founder and Chief Science Officer, Dr. Fillit spoke with CNBC Squawk Box, comparing #AntiAmyloids, the first class disease-modifying Alzheimer's drugs, to the first class of #chemotherapy drugs, as well as discussing the future of #Alzheimers care, how the #BiologyOfAging plays a role, and more. Watch the full interview here: https://cnb.cx/4aWFI1R

For many cancer patients, the use of cannabis to combat some of the side effects of treatment, such as nausea or insomnia, is a welcome therapy. But, with the persistent stigmatization of this modality, many health care providers feel uncertain in this terrain. We share advice on how to provide guidance about medical cannabis in our latest episode of How Healing Works. Follow the link to learn how you can confidently support the #WholePersonHealth of patients with this complementary therapy. 🔗 https://apple.co/3KsXnDv

🌐 From cancer to autoimmune diseases, biologics are game-changers in medicine. By mimicking the body’s natural processes, they tackle diseases at the root cause. 🩺 Are biologics the right choice for your health? Stay informed with the latest insights into these transformative treatments. https://lnkd.in/e4mkMywV #BiologicsInMedicine #ChronicIllness #HealthcareBreakthroughs